Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 233 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Advanced Cholangiocarcinoma Clear all
Terminated Phase 1 Interventional

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

NCT06420349
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound-Guided Biopsy
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

NCT00003427
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 11, 2026, 5:02 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

NCT07458347
View directory record Official record
Conditions
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
Interventions
KST-6051
Drug
Lead sponsor
Kestrel Therapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

NCT03829436
View directory record Official record
Conditions
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions
Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab
Drug
Lead sponsor
Tempest Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

NCT01007552
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Gemcitabine, Capecitabine and Bevacizumab
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 11, 2026, 5:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

NCT05451849
View directory record Official record
Conditions
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
Interventions
TC-510, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
TCR2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
San Franciso, California • Miami, Florida • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

NCT02989857
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Interventions
AG-120, Placebo
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

NCT03684811
View directory record Official record
Conditions
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
Interventions
FT-2102, Azacitidine, Nivolumab, Gemcitabine and Cisplatin
Drug · Biological
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Gilbert, Arizona • Aurora, Colorado • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

NCT06399757
View directory record Official record
Conditions
Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer
Interventions
APL-5125
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 11, 2026, 5:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842
View directory record Official record
Conditions
Advanced Solid Cancers
Interventions
BNT329, CA19-9-targeting monoclonal antibody
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Orlando, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

NCT00948935
View directory record Official record
Conditions
Biliary Cancer, Cholangiocarcinoma
Interventions
Gemcitabine, Irinotecan, Panitumumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 11, 2026, 5:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

NCT07488676
View directory record Official record
Conditions
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
ASP546C
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 11, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

NCT01229111
View directory record Official record
Conditions
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Periampullary Adenocarcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
cediranib maleate, oxaliplatin, leucovorin calcium, fluorouracil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Cleveland, Ohio • Columbus, Ohio • Mayfield Heights, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 11, 2026, 5:02 AM EDT
Completed No phase listed Observational

Advanced Endoscopy During COVID-19

NCT04385147
View directory record Official record
Conditions
Cholangitis, Secondary Biliary, Cholangiocarcinoma, Obstructive Jaundice, Pancreas Cancer, COVID-19, SARS-CoV-2
Interventions
Endoscopic management according to standard of care
Other
Lead sponsor
Al-Azhar University
Other
Eligibility
Not listed
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Albertson, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 11, 2026, 5:02 AM EDT
Recruiting Not applicable Interventional

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

NCT07224464
View directory record Official record
Conditions
Metastatic Solid Tumors, Stage 4 Cancer
Interventions
The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
Device
Lead sponsor
New Phase Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 11, 2026, 5:02 AM EDT
Not listed Phase 1Phase 2 Interventional

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

NCT00553683
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
cyclophosphamide, poly ICLC, hepatic artery embolization, 3-dimensional conformal radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer

NCT00107536
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
lapatinib ditosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

NCT04466891
View directory record Official record
Conditions
HER2-amplified Biliary Tract Cancers
Interventions
ZW25 (Zanidatamab)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 11, 2026, 5:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

NCT04203160
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
CPI 613, Gemcitabine, Cisplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 11, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

NCT00085410
View directory record Official record
Conditions
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 11, 2026, 5:02 AM EDT
Recruiting Phase 2 Interventional

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

NCT05422690
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Induction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:
Drug · Radiation
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 11, 2026, 5:02 AM EDT
Not listed Phase 1 Interventional

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NCT05311618
View directory record Official record
Conditions
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Cancer, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions
NGM438, Pembrolizumab (KEYTRUDA ®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

NCT03833661
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
Interventions
M7824
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 11, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

NCT01438554
View directory record Official record
Conditions
Solid Tumors, Thyroid Cancer, Soft-tissue Sarcoma, Cholangiocarcinoma
Interventions
Pazopanib, GSK1120212
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 11, 2026, 5:02 AM EDT